Cambrian Biopharma � VTA-300

Cambrian Biopharma is a biotechnology company focused on developing treatments that target the underlying biology of aging to extend human healthspan. They aim to create a pipeline of therapeutics addressing the various hallmarks of aging and age-related diseases. By targeting these hallmarks, Cambrian Biopharma seeks to develop therapies that can potentially delay, prevent, or treat multiple age-related diseases simultaneously. The company’s strategy involves acquiring, licensing, and investing in early-stage biotechnology companies and assets that target the fundamental biology of aging. They support these assets through their development, preclinical, and clinical phases to create innovative treatments for age-related diseases.Cambrian Biopharma was founded in 2021 by James Peyer. VTA-300 is being developed for the treatment of a localized form of muscular dystrophy with a cell therapy that combines the power of gene correction and induced pluripotent stem cell (iPSC) technology. Vita-300 uses iPSCs to engineer specific cell types designed to replace those that are defective in patients.